Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Accured Expenses (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Change in Accured Expenses data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 19.85% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $11.0 million, down 5.18%, while the annual FY2025 figure was $11.0 million, 5.18% down from the prior year.
  • Change in Accured Expenses reached $13.2 million in Q4 2025 per CLDX's latest filing, up from -$410000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $16.4 million in Q4 2024 and bottomed at -$5.0 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $1.1 million, with a median of -$480000.0 recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 839.27% in 2022, down 2592.91% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$550000.0 in 2021, then soared by 464.73% to $2.0 million in 2022, then crashed by 351.5% to -$5.0 million in 2023, then skyrocketed by 425.59% to $16.4 million in 2024, then fell by 19.85% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $13.2 million in Q4 2025, -$410000.0 in Q3 2025, and -$1.1 million in Q2 2025.